Abstract:Background: Tacrolimus (TAC) and mycophenolic acid (MPA) are commonly used immunosuppressive therapies after renal transplant. Our objective was to quantify TAC and MPA concentrations in peripheral blood mononuclear cells (PBMCs) using liquid chromatography tandem mass spectrometry (LC-MS/MS) and to evaluate and validate the performance of the methodology. A prospective follow-up cohort study was conducted to determine whether intracellular concentrations were associated with adverse outcomes in renal transplants. Methods: PBMCs were prepared using the Ficoll separation technique and purified with erythrocyte lysis. The cells were counted using Sysmex XN-3100 and then packaged and frozen according to a 50 μL volume containing 1.0 × 106 cells. TAC and MPA were extracted using MagnaBeads and quantified using an LC-MS/MS platform. The chromatography was run on a reversed-phase Waters Acquity UPLC BEH C18 column (1.7 μm, 50 mm × 2.1 mm) for gradient elution separation with a total run time of 4.5 min and a flow rate of 0.3 mL/min. Mobile phases A and B were water and methanol, respectively, each containing 2 mM ammonium acetate and 0.1% formic acid. Renal transplant recipients receiving TAC and MPA in combination were selected for clinical validation and divided into two groups: a stable group and an adverse outcome group. The concentrations were dynamically monitored at 5, 7, 14, and 21 days (D5, D7, D14, and D21) and 1, 2, 3, and 6 months (M1, M2, M3, and M6) after operation. Results: Method performance validation was performed according to Food and Drug Administration guidelines, showing high specificity and sensitivity. The TAC and MPA calibration curves were linear (r2 = 0.9988 and r2 = 0.9990, respectively). Both intra-day and inter-day imprecision and inaccuracy were less than 15%. Matrix effects and recoveries were satisfactory. The TAC and MPA concentrations in 304 "real" PBMC samples from 47 renal transplant recipients were within the calibration curve range (0.12 to 16.40 ng/mL and 0.20 to 4.72 ng/mL, respectively). There was a weak correlation between PBMC-C0TAC and WB-C0TAC (p < 0.05), but no correlation was found for MPA. The level of immunosuppressive intra-patient variation (IPV) was higher in PBMC at 77.47% (55.06, 97.76%) than in WB at 34.61% (21.90, 49.85%). During the dynamic change in C0TAC, PBMC-C0TAC was in a fluctuating state, and no stable period was found. PBMC-C0TAC did not show a significant difference between the stable and adverse outcome group, but the level of the adverse outcome group was generally higher than that of the stable group. Conclusions: Compared with conventional therapeutic drug monitoring, the proposed rapid and sensitive method can provide more clinically reliable information on drug concentration at an active site, which has the potential to be applied to the clinical monitoring of intracellular immunosuppressive concentration in organ transplantation. However, the application of PBMC-C0TAC in adverse outcomes of renal transplant should be studied further.

Comparison of enzyme multiplied immunoassay technique and high performance liquid chromatography in drug monitoring of mycophenolic acid in renal transplant patients

Pharmacokinetics Study of Mycophenolate Mofetil in Renal Transplantation Patients

Pharmacokinetics of Mycophenolic Acid in Chinese Kidney Transplant Patients

Comparison of a Point-of-Care Testing with Enzyme-Multiplied Immunoassay Technique and Liquid Chromatography Combined With Tandem Mass Spectrometry Methods for Therapeutic Drug Monitoring of Mycophenolic Acid: A Preliminary Study

Establishment of high-performance liquid chromatography and enzyme multiplied immunoassay technology methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients.

RP-HPLC Determination of Mycophenolic Acid in Serum of Liver Transplant Patients with Solid-Phase Extraction

Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase

Evaluation of the Area under the Curve of Enteric-Coated Mycophenolate Sodium Using a Limited Sampling Strategy in Chinese Kidney Transplant Recipients .

Cyclosporine A and Tacrolimus Combined with Enteric-Coated Mycophenolate Sodium Influence the Plasma Mycophenolic Acid Concentration - a Randomised Controlled Trial in Chinese Live Related Donor Kidney Transplant Recipients

A Study on Monitoring of MPA Plasm Concentration of Chinese Kidney Transplantation Recipients

Limited Sampling Strategies for Clinical Plasma Concentration Monitoring of Mycophenolic Acid

Mycophenolate Sodium Enteric-Coated Tablets Versus Mycophenolate Mofetil for Inhibition of Bone Marrow in Renal Transplant Repicients

External Validation of a Limited Sampling Strategy for the Estimation of Mycophenolic Acid Exposure Between Different Assay Methods: PETINIA and HPLC Methods

Short-Term Intensified Dosage Regimen of Mycophenolic Acid is Associated with Less Acute Rejection in Kidney Transplantation from Donation after Circulatory Death.

Monitoring Plasma Concentrations of Mycophenolic Acid in Patients with Renal Transplantation by Limited Sampling Strategy

Estimation of Mycophenolic Acid Area under the Curve with Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium

Dynamic Monitoring of Intracellular Tacrolimus and Mycophenolic Acid Therapy in Renal Transplant Recipients Using Magnetic Bead Extraction Combined with LC-MS/MS

A simple capillary zone electrophoresis method for the determination of mycophenolic acid in human plasma

245.5: Efficacy and Safety of an Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplant Recipients in China: A Prospective Cohort Study

Population Pharmacokineties of Mycophenolic Acid in Chinese Adult Renal Transplant Patients

Proton pump inhibitors on concentration of different preparations of mycophenolic acid in kidney transplantation recipients